Klinik und Diagnostik des Antiphospholipid-Syndroms

Zusammenfassung

Das Antiphospholipid-Syndrom ist eine klinische Diagnose, die durch eine spezielle Laboranalytik abzusichern ist. Das Spektrum der klinischen Symptome umfasst nicht nur arterielle oder venöse Gefäßverschlüsse, sondern auch eine Vielzahl neurologischer Symptome und schwangerschaftsassoziierter Probleme. Die Komplexität der Labortestung, Probleme der Standardisierung und der Befundinterpretation werden erörtert. Die Fortschritte und Grenzen der diagnostischen Möglichkeiten sollen aufgezeigt werden und es dem Kliniker ermöglichen, Befunde kritisch zu hinterfragen.

Summary

The diagnosis of antiphospholipid syndrome is based on clinical symptoms and is verified by laboratory testing. The spectrum of clinical symptoms includes not only arterial or venous thrombosis, a variety of neurological manifestations as well as pregnancy associated complications have been defined as relevant for the diagnosis. This article discusses the complexity of laboratory testing, problems of its standardisation and interpretation of test results. Progress and limitations of laboratory analysis are compared and the clinician will learn to read lab results with caution.

Schlüsselwörter

Antiphospholipid-Syndrom - Antiphospholipid-Antikörper - Lupusantikoagulans - erworbene Thrombophilie

Keywords

Antiphospholipid syndrome - antiphospholipid antibodies - Lupus-anticoagulant - acquired thrombophilia

• Literatur

• 1 APASS.. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 2912: 576-584.
• 2 Arnout J, Vanrusselt E, Huybrechts E. at al. Optimization of the dilute prothrombin time for the detection of the lupus antikoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 1994; 87: 94-99.
• 3 Arnout J, Vermylen J. Current status an implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003; 1: 931-942.
• 4 Asherson RA, Cervera R, de Groot PG. et al. Catastrophic antiphospholipid syndrome: international concensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530-534.
• 5 Balada E, Ordi-Ros J, Paredes F. et al. Antiphosphatidylethanolamine contribute to diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. Scand J Rheumatol 2001; 30: 235-241.
• 6 Blank M, Shoenfeld Y. Antiphosphatidylserin antibodies and reproductive failure. Lupus 2004; 13: 661-665.
• 7 Blohorn A, Guegan-Massardier E. Triquenot et al. Antiphospholipid Antibodies in the acute phase of cerebral ischemia in young adults: a descriptive study of 139 patients. Cerebrovasc Dis 2002; 13: 156-162.
• 8 Bizzaro N, Ghirardello A, Zampieri S. et al. Anti- Prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-yera longitudinal study. J Thromb Haemost 2007; 5: 1158-1164.
• 9 Bouma B, de Groot PG, van den Elsen JM. et al. Adhesion mechanism of human ®2-GPI to phospholipids based on ist crystal structure. EMBO J 1999; 18: 5166-5274.
• 10 Brandt JT, Triplett DA, Alving B. et al. Criteria for the diagnosis of lupus anticuagulant: an update. Thromb Haemost 1995; 74: 1185-1190.
• 11 Cowchock S, Reese EA. and the Organizing Group of the Antiphospholipid Antibody Treatment Trial. Do low-risk pregnant women with antiphospholipid Antibodies need to be treated?. Am J Obst Gynecol 1997; 176: 1099-1100.
• 12 Cervera R, Piette J-C, Font J. et al. Antiphospholipid syndrome. Clinical and immunologic manifestations an patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46: 1019-1027.
• 13 Chang S, Tillema V, Scherr D. A percent correction“ formula for evaluation of mixing studies. Am J Clin Path 2002; 117: 62-73.
• 14 Clifford K, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod 1997; 12: 387-389.
• 15 Conley C, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31: 621-622.
• 16 Crowther MA, Ginsberg JS, Julian J. et al. A comparison of two intensities of warfarin for the pre- vention of recurrent thrombosis in patients with the antiphospholipid syndrome. N Engl J Med 1995; 332: 993-997.
• 17 Derksen RH, de Groot PG, Kappelle LJ. Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. Neurology 2003; 61: 111-114.
• 18 Derksen R, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid Syndrome. Arthritis Rheum 2004; 50: 1028-1039.
• 19 Ebeling F, Pattersson T, Muukkonen L. et al. ®2-glycoprotein I antibodies in patients with thrombosis. Scan J Clin Lab 2003; 63: 11-18.
• 20 Empson M, Lassere M, Craig JC. et al. Recurrent pregnancy loss with antiphospholipid antibody: A systemic review of therapeutic trials. Obst Gynecol 2002; 99: 135-144.
• 21 Erkan D, Harrison MJ, Levy R. et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56: 2382-2391.
• 22 Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: A randomised, controlled trial of treatment. Obstet Gynecol 2002; 100: 408-413.
• 23 Feinstein D, Rapaport SI. Acquired inhibitors of blood Coagulation. Prog Hemost Thromb 1972; 1: 75.
• 24 Finazzi G, Marchioli R. Brancaccio at al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphsopholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-853.
• 25 Galli M, Comfurius P, Maassen C. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547.
• 26 Galli M, Ruggeri L, Barbui T. Differential effects on anti-®2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998; 91: 1999-2004.
• 27 Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the aPL syndrome. Blood 1999; 93: 2149-2157.
• 28 Galli M, Luciani D, Bertolini G. et al. Lupus antigoagulants are stronger risk factor of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a review of the literature. Blood 2002; 101: 1827-1832.
• 29 Ginsberg JS. Use of antithrombotic agents during pregnancy. Chest 2004; 126: 627S-644S.
• 30 De Groot PG, Lutters B, Derksen HMW. et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005; 3: 1993-1997.
• 31 Harris EN, Gharavi AE, Boey ML. et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-1214.
• 32 Hartung K-J, Lutze G, Luley C. Untersuchungen zur Lupusantikoagulanz-Empfindlichkeit“ verschiedener aPTT-Reagenzien. J Lab Med 1997; 21: 162-166.
• 33 Jones DW, Gallimore MJ, Winter M. Pseudofactor XII deficiency and phospholipid antibodies. Thromb Haemost 1996; 75: 696-697.
• 34 Laskin CA, Bombardier C, Hannah ME. et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337: 148-153.
• 35 Laurell AB, Nilsson IM. Hypergammaglobulinemia, circulationg anticoagulant and biologic false positive Wassermann reaction: a studying two cases. J Lab Clin Med 1957; 49: 694-707.
• 36 Loelinger A. Prothrombin as a cofactor of the circulating anticoagulant in systemic lupus erythematosus. Thromb Diath Haemorrh 1959; 3: 273-276.
• 37 Male C, Lechner K, Speiser W. et al. Transient lupus anticoagulants in children: stepwise disappereance of diagnsotic features. Thromb Haemost 2000; 83: 174-175.
• 38 Malia RG, Cooper SM, Faulkner K. et al. The specificity of platelet neutralization procedure. Thromb Haemost 1993; 69: 2416.
• 39 McNeil HP, Simpson RJ, Chesterman CN. et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: ®2-GPI-2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4129-4124.
• 40 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
• 41 Nash MJ, Camilleri RS, Kunka S. et al. The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies. J Thromb Haemostas 2004; 2: 1077-1081.
• 42 Pangborn MC. Isolation and purification of a serologically active phopsholipid from beef heart. J Biol Chem 1942; 143: 247.
• 43 Pengo V, Biasiolo A, Pegoraro C. et al. A two-step coagulation test to identify anti-®2-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004; 2: 702-707.
• 44 Pengo V, Biasiolo A, Gresele P. et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 2007; 5: 925-930.
• 45 Rai R. Obstetric management of Antiphospholipid Syndrome. J Autoimmunity 2000; 15: 203-207.
• 46 Reber G, Arvieux J, Comby E. at al. Multicenter evaluation of nine commercial kits for the quantification of anticardiolipin antibodies. Thromb Haemost 1995; 73: 444-452.
• 47 Reber G, Schousboe I, Tincani A. et al. Inter-laboratory variability of anti-®2-glycoprotein I measurement. A collaborative study in the frame of the European forum on antiphospholipid antibodies standardisation group. Thromb Haemost 2002; 88: 66-73.
• 48 Ruiz-Irastorza G, Kamashta MA. Lupus and pregnancy: ten questions and some answers. Lupus 2008; 17: 416-420.
• 49 Runchey SS, Falsom Ar, Tsai MY. et al. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 2002; 119: 1005-1010.
• 50 Salemink I, Blezer R, Willems GM. et al. Antibodies to b2-GPI assoziated with antiphospholipid syndrome suppress the inhibitory effect of tissue factor pathway inhibitor. Thromb Haemost 2000; 84: 653-656.
• 51 Stray-Peterson B, Stray-Peterson S. Etiologic factors and subsequent reproductive performance in 195 couples with a prio history of habitual abortion. Am J Obst Gynecol 1984; 148: 140-146.
• 52 Thom J, Ivey L, Eikelboom J. Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant. J Thromb Haemost 2003; 1: 2689-2691.
• 53 Tincani A, Allegri F, Sanmarco M. et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations. A cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86: 575-583.
• 54 Triolo G, Ferrante A, Ciccia F. et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2004; 50: 1017-1018.
• 55 Wahl DG, Guillemin F, de Maistre E. et al. Metaanalysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease of previous thrombosis. Lupus 1998; 7: 15-22.
• 56 Wassermann A, Neisser A, Bruck C. Eine serodiagnostische Reaktion bei Syphilis. Dtsch Med Wochenschr 1906; 32: 745.
• 57 Wijns W, Daoud N, Droeshout I. et al. Evaluation of three phospholipid neutralization procedures for lupus anticoagulant detection. Thromb Haemost 1993; 69: 1748.
• 58 Wilson WA, Gharavi AE, Koike T. et al. International consensus statement on preleminary classification criterea for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-1311.